1stOncology™: Cancer Intelligence Service – Page 11593 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

I-Mab Announces Upcoming Participation at January Conferences

On December 23, 2020 I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, reported its participation in the following conferences in January (Press release, I-Mab Biopharma, DEC 23, 2020, View Source [SID1234573236]). Details of the conferences and management presentation are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

H.C. Wainwright BioConnect 2021 Conference (Virtual)
Presentation: Monday, January 11, 2021 at 6:00 a.m. EST
Presenters: Dr. Jingwu Zang, Founder, Honorary Chairman and Director, Mr. Jielun Zhu, Director and Chief Financial Officer, and Ms. Leah Liu, Senior IR Director

Webcast link: View Source The webcast will also be available under "Event Calendar" on IMAB’s IR website at View Source

Citi Greater China Healthcare Corporate Day 2021 (Virtual)
Management participants: Dr. Jingwu Zang, Founder, Honorary Chairman and Director, Dr. Joan Huaqiong Shen, Director and Chief Executive Officer, Mr. Jielun Zhu, Director and Chief Financial Officer, and Ms. Leah Liu, Senior IR Director

One-on-one and small group meetings: January 14-15, 2021

For more information, please contact your Citi representative.

UBS Greater China Conference 2021 (Virtual)
Management participants: Dr. Jingwu Zang, Founder, Honorary Chairman and Director, Dr. Joan Huaqiong Shen, Director and Chief Executive Officer, Mr. Jielun Zhu, Director and Chief Financial Officer, and Ms. Leah Liu, Senior IR Director

One-on-one and small group meetings: January 18-22, 2021

ViewRay to Present at the 39th Annual J.P. Morgan Healthcare Conference

On December 23, 2020 ViewRay, Inc. (NASDAQ: VRAY) reported its participation in the 39th Annual J.P. Morgan Healthcare Conference (Press release, ViewRay, DEC 23, 2020, View Source [SID1234573235]). Scott Drake, President and CEO, is scheduled to present at 10:50 a.m. Eastern Time on Thursday, January 14, 2021.

An audio webcast of the Company’s presentation will be available on the "Financial Events and Webinars" portion of ViewRay’s investor website at View Source A replay of the webcast will be available for 14 days after the date of the presentation.

CNS Pharmaceuticals Announces Pricing of $10.0 Million Public Offering

On December 23, 2020 CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, reported the pricing of an underwritten public offering of 5,000,000 shares of common stock and warrants to purchase up to 2,500,000 shares of common stock (Press release, CNS Pharmaceuticals, DEC 23, 2020, View Source [SID1234573234]). The shares of common stock and warrants are being sold together at a combined public offering price of $2.00 per share and warrant. The warrants will have an exercise price of $2.20 per share, will be immediately exercisable and will expire five years from the date of issuance. The Company has granted the underwriter a 45-day option to purchase up to an additional 750,000 shares of common stock and/or 375,000 warrants to cover over-allotments, if any.

The Company intends to use the net proceeds from this offering for its Phase 2 trial for Berubicin, other research and development, and for working capital. The offering is expected to close on or about December 28, 2020, subject to customary closing conditions.

A.G.P./Alliance Global Partners is acting as the sole book-running manager for the offering.

This offering is being made pursuant to an effective registration statement on Form S-1 (No. 333-251530) previously filed with the U.S. Securities and Exchange Commission (the "SEC") and declared effective on December 22, 2020. The offering is being made only by means of a prospectus. A final prospectus relating to the proposed offering will be filed and made available on the SEC’s website. A copy of the final prospectus relating to the offering may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022 or via telephone at 212-624-2060 or email: [email protected]. Before investing in this offering, interested parties should read the prospectus.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

A2 Biotherapeutics Enters Into Collaboration Agreement With Merck to Develop Allogeneic Cell Therapy for Solid Tumor Cancers

On December 23, 2020 A2 Biotherapeutics (www.a2bio.com), a biotechnology company developing innovative cell therapies for cancer patients with solid tumors, reported that it has entered into an agreement with Merck, known as MSD outside the United States and Canada, in which A2 will continue research and preclinical development of its undisclosed Tmod cell therapy candidate (its third candidate therapy), with the parties to co-fund A2’s clinical development and allogeneic manufacturing activities through Phase 1 (Press release, A2 Biotherapeutics, DEC 23, 2020, View Source [SID1234573233]). Merck will assist with preclinical development and has the option to exclusively develop, manufacture and commercialize the candidate following Phase 1.

A2’s Tmod engineered T cells uniquely combine a potent activating mechanism to kill tumor cells with a blocking mechanism that protects normal cells from harm by exploiting the loss of genetic material in tumors. Tmod engineered T cells have the potential to make existing targets safer and more effective by protecting normal cells and delivering a more therapeutically effective dose to kill the tumor cells.

"In vitro studies have provided compelling evidence supporting the view that Tmod-based cell therapy can distinguish tumor cells from normal cells, across multiple tumor targets," said Dr. Roger M. Perlmutter, President, Merck Research Laboratories. "We hope that the combined efforts of Merck Research Laboratories and A2 Biotherapeutics will enable the application of this ingenious approach to improve the treatment of patients suffering from refractory solid tumors."

Under the agreement A2 will receive an upfront payment, and will be eligible for opt-in and milestone payments, plus royalties on sales of any approved product. A2 will also receive from Merck an equity investment and reimbursement of certain expenses. Merck has the option to designate a new Tmod program with increased economic terms.

"This transaction extends our cash runway on the heels of our successful $71.5M Series B in October. It also brings Merck’s immunotherapy and other expertise for the Tmod candidate especially in the later stages of development, manufacturing and commercialization and enables A2 to build allogeneic product development and manufacturing capabilities," said Scott Foraker, President and CEO of A2 Biotherapeutics.

A2 will continue to pursue its first two Tmod product candidates using its autologous manufacturing to reduce the number of variables for clinical proof of concept and expedite timelines. A2 anticipates that the successful development of its allogeneic Tmod candidate therapy will enable subsequently developed allogeneic Tmod candidates.

Novocure to Participate in the 39th Annual J.P. Morgan Virtual Healthcare Conference

On December 23, 2020 Novocure (NASDAQ: NVCR) reported that it will participate virtually in the 39th Annual J.P. Morgan Healthcare Conference on January 11 through January 14, 2021 (Press release, NovoCure, DEC 23, 2020, View Source [SID1234573232]). William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts at 8:20 a.m. EST on January 12, 2021. Management will also participate in one-on-one meetings with investors throughout the event.

A live audio webcast of the presentation and all presentation materials can be accessed from the Investor Relations page of Novocure’s website, www.novocure.com/investor-relations/, and will be available for replay for at least 14 days following the event. Novocure has used, and intends to continue to use, its investor relations website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.